Identification of Jaundice in Newborns Using Smartphones

Jaundice, Neonatal Clinical Trial

Official title:

Identification of Jaundice in Newborns Using Smartphones

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04182555
• Other study ID #: 2018/1608
• Status: Completed
• Phase: N/A
• Start date: August 3, 2020
• Est. completion date: September 15, 2020

Study information

• Verified date: September 2022
• Source: St. Olavs Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neonatal jaundice is a common and most often harmless condition. However, when unrecognized it can be fatal or cause serious brain injury. Three quarters of these deaths are estimated to occur in the poorest regions of the world. The treatment of jaundice, phototherapy, is in most cases easy, low-cost and harmless. The crucial point in reducing the burden of disease is therefore to identify then children at risk. This results in the need for low-cost, reliable and easy-to-use diagnostic tools that can identify newborns with jaundice. Based on previous research on the bio-optics of jaundiced newborn skin, a prototype of a smartphone application was developed and tested in a pilot study and the application refined. This smartphone application will now be evaluated in a clinical trial set in two hospitals in Norway. The smartphone application gives immediate estimates of bilirubin values in newborns, and these estimates will be compared to the bilirubin levels measured in standard blood samples, as well as the results from ordinary transcutaneous measurement devices.

Description:

The smartphone jaundice app system works by taking pictures of newborns with a custom-made color calibration card placed on their chest. This makes it possible to measure the skin color precisely regardless of the specific light source that is used to illuminate the newborn. The measured skin color is then compared with items in a database of simulated newborn skin colors. These simulated newborn skin colors have been created using numerical simulations of how light moves through skin, with varying skin parameters including, but not limited to, skin thickness, blood concentration, melanin, and of course bilirubin, the pigment that causes jaundice. By comparing the measured skin color with the simulated skin colors that are most similar to it, the investigators can then estimate the bilirubin concentration in the newborn's skin by e.g. averaging the bilirubin concentrations used to create these simulated skin colors. In a group of 200 newborns with varying degree of jaundice, correlation between smartphone bilirubin estimates will be compared with total serum bilirubin and standard transcutaneous bilirubinometry.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: September 15, 2020
• Est. primary completion date: September 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 14 Days

Eligibility

Inclusion Criteria:

• Born in St.Olavs hospital, Trondheim or in Haugesund Hospital, Norway
• Born with gestational age >36+6
• Birth weight = 2500g and <4500g
• Age 1 - <15 days
• Are having a blood sample performed, as newborn screening or for jaundice assessment Exclusion criteria:

Infants needing intensive treatment. This includes:

• Infants in the need for respiratory support
• Infants with conditions that could compromise skin circulation, as sepsis, heart failure or other
• Infants that have received phototherapy

Related Conditions & MeSH terms

• Hyperbilirubinemia
• Hyperbilirubinemia, Neonatal
• Jaundice
• Jaundice, Neonatal

Intervention

Device:
• Bilirubin estimates from Smartphone Application
Bilirubin estimates through color analysis of digital images obtained through smartphone application.

Diagnostic Test:
• Bilirubin concentration measured in standard blood samples
Bilirubin measured in total serum bilirubin.

Device:
• Bilirubin estimates from standard transcutaneous device
Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)

Other:
• Visual assessment of jaundice
Degree of jaundice will be assessed by Kramer scale

Locations

Country	Name	City	State
Norway	Haugesund Hospital	Haugesund
Norway	St Olavs Hospital	Trondheim

Sponsors (3)

Lead Sponsor	Collaborator
St. Olavs Hospital	Helse Fonna, Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Smartphone application sensitivity	Sensitivity of the smartphone application to detect severe jaundice, defined as total serum bilirubin value > 250 umol/l.	5 minutes
Secondary	Repeatability	To evaluate the repeatability of multiple measurements with the new smartphone tool	5 min
Secondary	Correlation between bilirubin estimates by smartphone pictures and by total serum bilirubin	Estimate of bilirubin levels from smartphone pictures, compared with bilirubin measurements in total serum. Correlation will be expressed by Pearson correlation coefficient, r.	5 minutes
Secondary	Correlation between bilirubin estimates by smartphone pictures and by standard transcutaneous readings.	To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from a standard transcutaneous device in newborns with varying degree of jaundice. Correlation will be expressed by Pearson correlation coefficient, r.	5 minutes
Secondary	Correlation between bilirubin estimates by smartphone pictures and visual assessment of jaundice	- To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from visual inspection in newborns with varying degree of jaundice	5 min